Evidence map›Paper›PMID 42834216›Full record

ReviewReviews of physiology, biochemistry and pharmacology2027

AA in Rheumatoid Arthritis and Lupus.

Undurti N Das

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reviews of physiology, biochemistry and pharmacology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Undurti N DasUND Life Sciences, Battle Ground, WA, USA. undurti@lipidworld.com.ORCID https://orcid.org/0000-0002-0191-9508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation and immune dysregulation are at the center of various diseases, including autoimmune diseases, especially rheumatoid arthritis (RA) and systemic lupus erythematosus (lupus). In general, corticosteroids, disease-modifying drugs, and monoclonal antibodies against IL-6 and TNF-α, JAK inhibitors, and various other immunomodulators are extensively used in the treatment of RA and lupus. It is known that EFA (essential fatty acid) metabolism, especially that of AA, is altered in RA and lupus. It is proposed that metabolism of AA and of other PUFAs may play a role in predicting disease progression, prognosis, and response to treatments offered. For this discussion, a better understanding of the interaction between corticosteroids and EFA metabolism is needed.Corticosterone acts on three classes of PLA

Indexed as

Arthritis, RheumatoidLupus Erythematosus, SystemicAdrenal Cortex HormonesAnimalsHumansSpecialized Pro-Resolving MediatorsAdrenal Cortex HormonesCorticosteroidsInflammationLipoxin A4LupusMaresinsPhospholipaseProtectinsResolvinsRheumatoid arthritis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.